527 related articles for article (PubMed ID: 31948390)
1. Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study.
Liu T; Yang HL; Gu L; Hui J; Omorogieva O; Ren MX; Wang XH
BMC Cardiovasc Disord; 2020 Jan; 20(1):22. PubMed ID: 31948390
[TBL] [Abstract][Full Text] [Related]
2. Trends in Prevalence of Non-Valvular Atrial Fibrillation and Anticoagulation Therapy in a Japanese Region - Analysis Using the National Health Insurance Database.
Narita N; Okumura K; Kinjo T; Mikami J; Tsushima K; Takahashi R; Noro M; Hashimoto A; Sasaki T; Takaki M; Ishidoya E; Narita Y; Imai H; Ono E; Tomita H
Circ J; 2020 Apr; 84(5):706-713. PubMed ID: 32213724
[TBL] [Abstract][Full Text] [Related]
3. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
Martinez C; Katholing A; Wallenhorst C; Freedman SB
Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use.
Lee SR; Choi EK; Kwon S; Jung JH; Han KD; Cha MJ; Oh S; Lip GYH
Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005894. PubMed ID: 32160790
[TBL] [Abstract][Full Text] [Related]
5. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
6. Stroke Risk Status, Anticoagulation Treatment, and Quality-of-Life in Chinese Patients with Atrial Fibrillation: China Registry of Atrial Fibrillation (CRAF).
Sun Y; Zhu J; Ma C; Liu S; Yang Y; Hu D
Cardiovasc Ther; 2019; 2019():7372129. PubMed ID: 31772614
[No Abstract] [Full Text] [Related]
7. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry.
Cools F; Wollaert B; Vervoort G; Verstraete S; Voet J; Hermans K; Heyse A; De Wolf A; Hollanders G; Boussy T; Anné W; Vercammen J; Faes D; Beutels M; Mairesse G; Purnode P; Blankoff I; Vandergoten P; Capiau L; Allu J; Bassand JP; Kayani G;
Acta Cardiol; 2019 Aug; 74(4):309-318. PubMed ID: 30369290
[No Abstract] [Full Text] [Related]
8. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
[TBL] [Abstract][Full Text] [Related]
10. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
[TBL] [Abstract][Full Text] [Related]
12. Rates and Determinants for the Use of Anticoagulation Treatment before Stroke in Patients with Known Atrial Fibrillation.
Giustozzi M; Agnelli G; Quattrocchi S; Acciarresi M; Alberti A; Caso V; Vedovati MC; Venti M; Paciaroni M
Cerebrovasc Dis Extra; 2020; 10(2):44-49. PubMed ID: 32375143
[TBL] [Abstract][Full Text] [Related]
13. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
[TBL] [Abstract][Full Text] [Related]
14. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
[TBL] [Abstract][Full Text] [Related]
15. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study.
Krittayaphong R; Winijkul A; Methavigul K; Wongtheptien W; Wongvipaporn C; Wisaratapong T; Kunjara-Na-Ayudhya R; Boonyaratvej S; Komoltri C; Kaewcomdee P; Yindeengam A; Sritara P;
BMC Cardiovasc Disord; 2018 Aug; 18(1):174. PubMed ID: 30144802
[TBL] [Abstract][Full Text] [Related]
16. Factors That Affect Time to Switch From Warfarin to a Direct Oral Anticoagulant After Change in the Reimbursement Criteria in Patients With Atrial Fibrillation.
Park S; Je NK
J Cardiovasc Pharmacol Ther; 2020 Jan; 25(1):57-64. PubMed ID: 31405298
[TBL] [Abstract][Full Text] [Related]
17. Age-Related Differences in the Clinical Characteristics and Treatment of Elderly Patients With Atrial Fibrillation in Japan - Insight From the ANAFIE (All Nippon AF In Elderly) Registry.
Hiasa KI; Kaku H; Inoue H; Yamashita T; Akao M; Atarashi H; Koretsune Y; Okumura K; Shimizu W; Ikeda T; Toyoda K; Hirayama A; Yasaka M; Yamaguchi T; Teramukai S; Kimura T; Kaburagi J; Takita A; Tsutsui H
Circ J; 2020 Feb; 84(3):388-396. PubMed ID: 31969518
[TBL] [Abstract][Full Text] [Related]
18. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
[TBL] [Abstract][Full Text] [Related]
19. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
